# HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

> **NCT07712705** · PHASE3 · COMPLETED · sponsor: **Newsoara Biopharma Co., Ltd.** · enrollment: 515 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** HPP737
- **DRUG:** Placebo matching HPP737

## Key facts

- **NCT ID:** NCT07712705
- **Lead sponsor:** Newsoara Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-20
- **Primary completion:** 2023-09-29
- **Final completion:** 2025-02-20
- **Target enrollment:** 515 (ACTUAL)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712705, "HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*